Gregory A. Abel

7.5k total citations · 2 hit papers
221 papers, 4.8k citations indexed

About

Gregory A. Abel is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Gregory A. Abel has authored 221 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 75 papers in Public Health, Environmental and Occupational Health and 52 papers in Hematology. Recurrent topics in Gregory A. Abel's work include Acute Myeloid Leukemia Research (46 papers), Palliative Care and End-of-Life Issues (43 papers) and Health Systems, Economic Evaluations, Quality of Life (29 papers). Gregory A. Abel is often cited by papers focused on Acute Myeloid Leukemia Research (46 papers), Palliative Care and End-of-Life Issues (43 papers) and Health Systems, Economic Evaluations, Quality of Life (29 papers). Gregory A. Abel collaborates with scholars based in United States, Canada and United Kingdom. Gregory A. Abel's co-authors include Oreofe O. Odejide, Ann S. LaCasce, Haiden A. Huskamp, Aaron N. Winn, Nancy L. Keating, Stacie B. Dusetzina, Heidi D. Klepin, Angel M. Cronin, Richard M. Stone and Jane A. Driver and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Gregory A. Abel

205 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

2013 609 citations Leo I. Gordon, Ann S. LaCasce et al. Blood profile →
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

2013 389 citations Gregory A. Abel et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory A. Abel United States	36	1.7k	1.3k	1.2k	982	809	221	4.8k
Eva Culakova United States	38	2.8k 1.6×	550 0.4×	593 0.5×	1.0k 1.1×	364 0.4×	180	7.0k
Ivo Abraham United States	39	1.0k 0.6×	631 0.5×	315 0.3×	648 0.7×	537 0.7×	306	6.4k
Grace L. Smith United States	44	2.4k 1.4×	740 0.6×	792 0.7×	428 0.4×	268 0.3×	205	8.9k
Fabio Efficace Italy	46	3.1k 1.8×	1.3k 1.0×	284 0.2×	975 1.0×	1.0k 1.3×	215	6.6k
Kimberly Webster United States	25	2.8k 1.6×	583 0.4×	529 0.5×	517 0.5×	1.2k 1.4×	55	5.2k
Kathleen J. Yost United States	37	3.0k 1.8×	1.2k 0.9×	455 0.4×	232 0.2×	976 1.2×	159	7.2k
Corneel Coens Belgium	47	3.7k 2.2×	854 0.6×	352 0.3×	431 0.4×	686 0.8×	143	9.0k
F. Lennie Wong United States	32	1.4k 0.8×	1.5k 1.1×	198 0.2×	736 0.7×	1.8k 2.2×	140	4.8k
Lazzaro Repetto Italy	32	3.0k 1.8×	848 0.6×	601 0.5×	662 0.7×	289 0.4×	101	6.3k
Isaac Nuamah United States	30	642 0.4×	551 0.4×	327 0.3×	695 0.7×	433 0.5×	98	5.2k

Countries citing papers authored by Gregory A. Abel

Since Specialization

Citations

This map shows the geographic impact of Gregory A. Abel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Abel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Abel more than expected).

Fields of papers citing papers by Gregory A. Abel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory A. Abel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Abel. The network helps show where Gregory A. Abel may publish in the future.

Co-authorship network of co-authors of Gregory A. Abel

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Abel. A scholar is included among the top collaborators of Gregory A. Abel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Abel. Gregory A. Abel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Efficace, Fabio, et al.. (2025). Timely Reporting of Patient-Reported Outcomes in Cancer Clinical Trials: An Ethical Imperative. Journal of Clinical Oncology. 43(10). 1176–1179. 3 indexed citations

Hantel, Andrew, Emily Senay, Cristina Richie, et al.. (2024). A focus group study of ethical issues during climate-informed health decision-making. Nature Climate Change. 14(10). 1040–1046. 10 indexed citations

DeZern, Amy E., Michael Otterstatter, Nancy Gillis, et al.. (2024). Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS). Blood. 144(Supplement 1). 1831–1831.

La, Jennifer, Tammy T. Hshieh, J. Michael Gaziano, et al.. (2024). Potentially inappropriate medications and their association with frailty, unplanned hospitalizations, and mortality in patients with cancer treated in the national U.S. Veterans Affairs Healthcare System.. Journal of Clinical Oncology. 42(16_suppl). 1620–1620. 1 indexed citations

DuMontier, Clark, et al.. (2024). Tailoring Therapy in Older Adults With Hematologic Malignancies. American Society of Clinical Oncology Educational Book. 44(3). e432220–e432220. 3 indexed citations

Hantel, Andrew, Yating Wang, Ivy Abraham, et al.. (2024). Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation.. Journal of Clinical Oncology. 42(16_suppl). 1589–1589.

Marron, Jonathan M., et al.. (2023). Clinical ethics consultation documentation in the era of open notes. BMC Medical Ethics. 24(1). 27–27. 4 indexed citations

Patel, Shyam A., Rena Zheng, Lloyd Hutchinson, et al.. (2023). Sole DNMT3A/TET2/ASXL1 Mutations Define a Distinct Clinical Trajectory for Patients with Clonal Hematopoiesis. Blood. 142(Supplement 1). 4068–4068. 2 indexed citations

Kelkar, Amar H., Chantal Kerssens, Hajime Uno, et al.. (2023). Feasibility of Utilizing a Virtual Health Assistant during Inpatient Reduced-Intensity Allogeneic Transplantation. Blood. 142(Supplement 1). 5104–5104.

10.

Kelkar, Amar H., Edward R. Scheffer Cliff, Caron A. Jacobson, et al.. (2023). Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma. Annals of Internal Medicine. 176(12). 1625–1637. 18 indexed citations

11.

Abel, Gregory A., Dana E. Rollison, Nancy Gillis, et al.. (2023). Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Advances. 7(14). 3506–3515. 6 indexed citations

12.

Kelkar, Amar H., et al.. (2022). Cost-Effectiveness of CD19 Chimeric Antigen Receptor T Cell Therapy Versus Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma in First Relapse. Transplantation and Cellular Therapy. 28(3). S332–S333. 2 indexed citations

13.

DuMontier, Clark, Brad Manor, Marcia A. Testa, et al.. (2022). Virtual frailty assessment for older adults with hematologic malignancies. Blood Advances. 6(18). 5360–5363. 6 indexed citations

14.

Fillmore, Nathanael R., Clark DuMontier, Jennifer La, et al.. (2021). Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. JNCI Journal of the National Cancer Institute. 113(8). 1084–1093. 11 indexed citations

15.

Cronin, Angel M., Craig C. Earle, James A. Tulsky, et al.. (2019). How Do Blood Cancer Doctors Discuss Prognosis? Findings from a National Survey of Hematologic Oncologists. Journal of Palliative Medicine. 22(6). 677–684. 19 indexed citations

16.

Loh, Kah Poh, Huiwen Xu, Anthony L. Back, et al.. (2019). Patient‐hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study. Cancer. 126(6). 1306–1314. 21 indexed citations

17.

Zhang, Ling, Donald M. Stablein, Pearlie K. Epling‐Burnette, et al.. (2018). Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study. Blood. 132(Supplement 1). 4370–4370. 3 indexed citations

18.

Odejide, Oreofe O., Ling Li, Angel M. Cronin, et al.. (2017). Hospice Use Among Patients with Myeloma. Blood. 130. 346–346. 1 indexed citations

19.

Zeidan, Amer M., Amy J. Davidoff, Jessica B. Long, et al.. (2016). Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal of Haematology. 175(5). 829–840. 52 indexed citations

20.

Herrera, Alex F., Allison Crosby‐Thompson, Jonathan W. Friedberg, et al.. (2014). Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network. Cancer. 120(13). 1993–1999. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact